Animal models to assess the abuse liability of tobacco products: Effects of smokeless tobacco extracts on intracranial self-stimulation

Drug and Alcohol Dependence

Volumn 147, Issue , 2015, Pages 60-67

  Harris, Andrew C ^a,b,c   Tally, Laura ^a   Schmidt, Clare E ^a,c   Muelken, Peter ^a,c   Stepanov, Irina ^d   Saha, Subhrakanti ^d   Vogel, Rachel Isaksson ^d   LeSage, Mark G ^a,b,c  

^a MINNEAPOLIS MEDICAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Extract; Intracranial self stimulation; Nicotine; Non nicotine tobacco constituents; Policy; Smokeless tobacco

Indexed keywords

ALKALOID; NICOTINE; NICOTINIC RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AVERSIVE BEHAVIOR; BINDING AFFINITY; CAMEL SNUS; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXPOSURE; FOOD AND DRUG ADMINISTRATION; KODIAK WINTERGREEN; MALE; NONHUMAN; PRODUCT EXPOSURE; RAT; RECEPTOR BINDING; REINFORCEMENT; SELF STIMULATION; SMOKELESS TOBACCO; TOBACCO DEPENDENCE; ADDICTION; ANIMAL; CHEMICALLY INDUCED; ELECTROSTIMULATION; HUMAN; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; PROCEDURES; PSYCHOLOGY; SPRAGUE DAWLEY RAT;

ANIMALIA; NICOTIANA TABACUM; RATTUS;

ALKALOIDS; ANIMALS; BEHAVIOR, ADDICTIVE; ELECTRIC STIMULATION; HUMANS; INJECTIONS, INTRAVENTRICULAR; MALE; MODELS, ANIMAL; NICOTINE; RATS; RATS, SPRAGUE-DAWLEY; REINFORCEMENT (PSYCHOLOGY); SELF STIMULATION; TOBACCO USE DISORDER; TOBACCO, SMOKELESS;

EID: 84920998688     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2014.12.015     Document Type: Article

References (66)

1. Ambrose V., Miller J.H., Dickson S.J., Hampton S., Truman P., Lea R.A., Fowles J. Tobacco particulate matter is more potent than nicotine at upregulating nicotinic receptors on SH-SY5Y cells. Nicotine Tob. Res. 2007, 9:793-799.
2. Bardo M.T., Green T.A., Crooks P.A., Dwoskin L.P. Nornicotine is self-administered intravenously by rats. Psychopharmacology 1999, 146:290-296.
3. Bardo M.T., Rowlett J.K., Harris M.J. Conditioned place preference using opiate and stimulant drugs: a meta-analysis. Neurosci. Biobehav. Rev 1995, 19:39-51.
4. Bauco P., Wise R.A. Potentiation of lateral hypothalamic and midline mesencephalic brain stimulation reinforcement by nicotine: examination of repeated treatment. J. Pharmacol. Exp. Ther. 1994, 271:294-301.
5. Belluzzi J.D., Wang R., Leslie F.M. Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology 2005, 30:705-712.
6. Benjamini Y., Hochberg Y. Controlling the false discovery rate: a powerful and practical approach to multiple testing. in behavior genetics research. J. R. Stat. Soc. Ser. B: Stat. Methodol. 1995, 57:289-300.
7. Brennan K.A., Crowther A., Putt F., Roper V., Waterhouse U., Truman P. Tobacco particulate matter self-administration in rats: differential effects of tobacco type. Addict. Biol. 2013, (epub).
8. Brennan K.A., Laugesen M., Truman P. Whole tobacco smoke extracts to model tobacco dependence in animals. Neurosci. Biobehav. Rev. 2014, 47C:53-69.
9. Brennan K.A., Putt F., Roper V., Waterhouse U., Truman P. Nicotine and tobacco particulate self-administration: effects of mecamylamine, SCH23390 and ketanserin pretreatment. Curr. Psychopharmacol. 2013, 2:229-240.
10. Brennan K.A., Putt F., Truman P. Nicotine-, tobacco particulate matter- and methamphetamine-produced locomotor sensitisation in rats. Psychopharmacology 2013, 228:659-672.
11. Burris J.L., Carpenter M.J., Wahlquist A.E., Cummings K.M., Gray K.M. Brief, instructional smokeless tobacco use among cigarette smokers who do not intend to quit: a pilot randomized clinical trial. Nicotine Tob. Res. 2014, 16:397-405.
12. Caggiula A.R., Donny E.C., Palmatier M.I., Liu X., Chaudhri N., Sved A.F. The role of nicotine in smoking: a dual-reinforcement model. Nebr. Symp. Motiv. 2009, 55:91-109.
13. Changeux J.P. Nicotine addiction and nicotinic receptors: lessons from genetically modified mice. Nat. Rev. Neurosci. 2010, 11:389-401.
14. Chaudhri N., Caggiula A.R., Donny E.C., Palmatier M.I., Liu X., Sved A.F. Complex interactions between nicotine and nonpharmacological stimuli reveal multiple roles for nicotine in reinforcement. Psychopharmacology 2006, 184:353-366.
15. Clemens K.J., Caille S., Stinus L., Cador M. The addition of five minor tobacco alkaloids increases nicotine-induced hyperactivity, sensitization and intravenous self-administration in rats. Int. J. Neuropsychopharmacol. 2009, 12:1355-1366.
16. Cobb C.O., Weaver M.F., Eissenberg T. Evaluating the acute effects of oral, non-combustible potential reduced exposure products marketed to smokers. Tob. Control 2009, 19:367-373.
17. Costello M.R., Reynaga D.D., Mojica C.Y., Zaveri N.T., Belluzzi J.D., Leslie F.M. Comparison of the reinforcing properties of nicotine and cigarette smoke extract in rats. Neuropsychopharmacology 2014, 39:1843-1851.
18. De Biasi M., Salas R. Influence of neuronal nicotinic receptors over nicotine addiction and withdrawal. Exp. Biol. Med. 2008, 233:917-929.
19. Delnevo C.D., Wackowski O.A., Giovenco D.P., Manderski M.T., Hrywna M., Ling P.M. Examining market trends in the United States smokeless tobacco use: 2005-2011. Tob. Control 2014, 23:107-112.
20. Deyton L., Sharfstein J., Hamburg M. Tobacco product regulation--a public health approach. N. Engl. J. Med. 2010, 362:1753-1756.
21. Donny E.C., Chaudhri N., Caggiula A.R., Evans-Martin F.F., Booth S., Gharib M.A., Clements L.A., Sved A.F. Operant responding for a visual reinforcer in rats is enhanced by noncontingent nicotine: implications for nicotine self-administration and reinforcement. Psychopharmacology 2003, 169:68-76.
22. Dwoskin L.P., Crooks P.A., Teng L., Green T.A., Bardo M.T. Acute and chronic effects of nornicotine on locomotor activity in rats: altered response to nicotine. Psychopharmacology 1999, 145:442-451.
23. Foddai M., Dosia G., Spiga S., Diana M. Acetaldehyde increases dopaminergic neuronal activity in the VTA. Neuropsychopharmacology 2004, 29:530-536.
24. Fowler C.D., Arends M.A., Kenny P.J. Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice. Behav. Pharmacol. 2008, 19:461-484.
25. Fowler C.D., Lu Q., Johnson P.M., Marks M.J., Kenny P.J. Habenular alpha5 nicotinic receptor subunit signalling controls nicotine intake. Nature 2011, 471:597-601.
26. Gray J.N., Breland A.B., Weaver M., Eissenberg T. Potential reduced exposure products (PREPs) for smokeless tobacco users: clinical evaluation methodology. Nicotine Tob. Res 2008, 10:1441-1448.
27. Guillem K., Vouillac C., Azar M.R., Parsons L.H., Koob G.F., Cador M., Stinus L. Monoamine oxidase inhibition dramatically increases the motivation to self-administer nicotine in rats. J. Neurosci. 2005, 25:8593-8600.
28. Harris A.C., Mattson C., Lesage M.G., Keyler D.E., Pentel P.R. Comparison of the behavioral effects of cigarette smoke and pure nicotine in rats. Pharmacol. Biochem. Behav. 2010, 96:217-227.
29. Harris A.C., Pentel P.R., Burroughs D., Staley M.D., Lesage M.G. A lack of association between severity of nicotine withdrawal and individual differences in compensatory nicotine self-administration in rats. Psychopharmacology (Berl.) 2011, 217:153-166.
30. Harris A.C., Stepanov I., Pentel P.R., Lesage M.G. Delivery of nicotine in an extract of a smokeless tobacco product reduces its reinforcement-attenuating and discriminative stimulus effects in rats. Psychopharmacology (Berl.) 2012, 220:565-576.
31. Harrison A.A., Gasparini F., Markou A. Nicotine potentiation of brain stimulation reward reversed by DH beta E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats. Psychopharmacology (Berl.) 2002, 160:56-66.
32. Hatsukami D.K., Benowitz N.L., Donny E., Henningfield J., Zeller M. Nicotine reduction: strategic research plan. Nicotine Tob. Res. 2012, 15:1003-1013.
33. Hatsukami D.K., Ebbert J.O., Feuer R.M., Stepanov I., Hecht S.S. Changing smokeless tobacco products new tobacco-delivery systems. Am. J. Prev. Med. 2007, 33:S368-S378.
34. Hatsukami D.K., Perkins K.A., Lesage M.G., Ashley D.L., Henningfield J.E., Benowitz N.L., Backinger C.L., Zeller M. Nicotine reduction revisited: science and future directions. Tob. Control 2010, 19:e1-e10.
35. Huston-Lyons D., Kornetsky C. Effects of nicotine on the threshold for rewarding brain stimulation in rats. Pharmacol. Biochem. Behav. 1992, 41:755-759.
36. Kenny P.J., Polis I., Koob G.F., Markou A. Low dose cocaine self-administration transiently increases but high dose cocaine persistently decreases brain reward function in rats. Eur. J. Neurosci. 2003, 17:191-195.
37. Kornetsky C., Esposito R.U. Euphorigenic drugs: effects on the reward pathways of the brain. Fed. Proc. 1979, 38:2473-2476.
38. Kornetsky C., Esposito R.U., McLean S., Jacobson J.O. Intracranial self-stimulation thresholds: a model for the hedonic effects of drugs of abuse. Arch. Gen. Psychiatry 1979, 36:289-292.
39. Kotlyar M., Hertsgaard L.A., Lindgren B.R., Jensen J.A., Carmella S.G., Stepanov I., Murphy S.E., Hecht S.S., Hatsukami D.K. Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study. Cancer Epidemiol. Biomarkers Prev. 2011, 20:91-100.
40. Kotlyar M., Mendoza-Baumgart M.I., Li Z.Z., Pentel P.R., Barnett B.C., Feuer R.M., Smith E.A., Hatsukami D.K. Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge. Tob. Control 2007, 16:138-142.
41. Laviolette S.R., van der Kooy D. Blockade of mesolimbic dopamine transmission dramatically increases sensitivity to the rewarding effects of nicotine in the ventral tegmental area. Mol. Psychiatry 2003, 8:50-59.
42. Liu X., Palmatier M.I., Caggiula A.R., Donny E.C., Sved A.F. Reinforcement enhancing effect of nicotine and its attenuation by nicotinic antagonists in rats. Psychopharmacology 2007, 194:463-473.
43. Markou A., Koob G.F. Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol. Behav. 1992, 51:111-119.
44. Matta S.G., Balfour D.J., Benowitz N.L., Boyd R.T., Buccafusco J.J., Caggiula A.R., Craig C.R., Collins A.C., Damaj M.I., Donny E.C., Gardiner P.S., Grady S.R., Heberlein U., Leonard S.S., Levin E.D., Lukas R.J., Markou A., Marks M.J., McCallum S.E., Parameswaran N., Perkins K.A., Picciotto M.R., Quik M., Rose J.E., Rothenfluh A., Schafer W.R., Stolerman I.P., Tyndale R.F., Wehner J.M., Zirger J.M. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology 2007, 190:269-319.
45. O'Dell L.E. A psychobiological framework of the substrates that mediate nicotine use during adolescence. Neuropharmacology 2009, 56(Suppl. 1):263-278.
46. Paterson N.E., Balfour D.J., Markou A. Chronic bupropion differentially alters the reinforcing, reward-enhancing and conditioned motivational properties of nicotine in rats. Nicotine Tob. Res. 2008, 10:995-1008.
47. Pederson L.L., Nelson D.E. Literature review and summary of perceptions, attitudes, beliefs, and marketing of potentially reduced exposure products: communication implications. Nicotine Tob. Res. 2007, 9:525-534.
48. Rangiah K., Hwang W.T., Mesaros C., Vachani A., Blair I.A. Nicotine exposure and metabolizer phenotypes from analysis of urinary nicotine and its 15 metabolites by LC-MS. Bioanalysis 2011, 3:745-761.
49. Roiko S.A., Harris A.C., LeSage M.G., Keyler D.E., Pentel P.R. Passive immunization with a nicotine-specific monoclonal antibody decreases brain nicotine levels but does not precipitate withdrawal in nicotine-dependent rats. Pharmacol. Biochem. Behav. 2009, 93:105-111.
50. Sellings L.H., Baharnouri G., McQuade L.E., Clarke P.B. Rewarding and aversive effects of nicotine are segregated within the nucleus accumbens. Eur. J. Neurosci. 2008, 28:342-352.
51. Shram M.J., Funk D., Li Z., Le A.D. Periadolescent and adult rats respond differently in tests measuring the rewarding and aversive effects of nicotine. Psychopharmacology 2006, 186:201-208.
52. Spiller K., Xi Z.X., Li X., Ashby C.R., Callahan P.M., Tehim A., Gardner E.L. Varenicline attenuates nicotine-enhanced brain-stimulation reward by activation of alpha4beta2 nicotinic receptors in rats. Neuropharmacology 2009, 57:60-66.
53. Stepanov I., Biener L., Yershova K., Nyman A.L., Bliss R., Parascandola M., Hatsukami D.K. Monitoring tobacco-specific n-nitrosamines and nicotine in novel smokeless tobacco products: findings from round ii of the new product watch. Nicotine Tob. Res. 2014, 16:1070-1078.
54. Stepanov I., Jensen J., Biener L., Bliss R.L., Hecht S.S., Hatsukami D.K. Increased pouch sizes and resulting changes in the amounts of nicotine and tobacco-specific N-nitrosamines in single pouches of Camel Snus and Marlboro Snus. Nicotine Tob. Res. 2012, 14:1241-1245.
55. Stepanov I., Jensen J., Hatsukami D., Hecht S.S. New and traditional smokeless tobacco: comparison of toxicant and carcinogen levels. Nicotine Tob. Res. 2008, 10:1773-1782.
56. Stratton K., Shetty P., Wallace R., Bondurant S. Clearing the smoke: the science base for tobacco harm reduction--executive summary. Tob. Control 2001, 10:189-195.
57. Touiki K., Rat P., Molimard R., Chait A., de Beaurepaire R. Effects of tobacco and cigarette smoke extracts on serotonergic raphe neurons in the rat. Neuroreport 2007, 18:925-929.
58. U.S. Congress Family Smoking Prevention and Tobacco Control Act 2009, US Government Printing Office, Retrieved from http://wwwgpogov/.
59. Villegier A.S., Lotfipour S., McQuown S.C., Belluzzi J.D., Leslie F.M. Tranylcypromine enhancement of nicotine self-administration. Neuropharmacology 2007, 52:1415-1425.
60. Wilmouth C.E., Spear L.P. Adolescent and adult rats' aversion to flavors previously paired with nicotine. Ann. N. Y. Acad. Sci. 2004, 1021:462-464.
61. Wise R.A. Addictive drugs and brain stimulation reward. Annu. Rev. Neurosci. 1996, 19:319-340.
62. Wise R.A. Brain reward circuitry: insights from unsensed incentives. Neuron 2002, 36:229-240.
63. Wise R.A., Bauco P., Carlezon W.A., Trojniar W. Self-stimulation and drug reward mechanisms. Ann. N. Y. Acad. Sci. 1992, 654:192-198.
64. Xiao Y., Fan H., Musachio J.L., Wei Z.L., Chellappan S.K., Kozikowski A.P., Kellar K.J. Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them. Mol. Pharmacol. 2006, 70:1454-1460.
65. Xiao Y., Meyer E.L., Thompson J.M., Surin A., Wroblewski J., Kellar K.J. Rat alpha3/beta4 subtype of neuronal nicotinic acetylcholine receptor stably expressed in a transfected cell line: pharmacology of ligand binding and function. Mol. Pharmacol. 1998, 54:322-333.
66. Zeller M., Hatsukami D. The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US. Tob. Control 2009, 18:324-332.